Company profile

Mitchell Shuster Steiner
Incorporated in
Fiscal year end
Former names
Female Health Co
IRS number

VERU stock data

FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings
Securities sold
Number of investors


13 May 20
1 Jun 20
30 Sep 20


Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 9.94M 10.58M 8.73M 9.73M
Net income -810.51K -3.31M -3.06M -2.77M
Diluted EPS -0.01 -0.05 -0.05 -0.04
Net profit margin -8.15% -31.24% -35.06% -28.52%
Operating income -299.68K -1.78M -1.46M -1.84M
Net change in cash 2.14M
Cash on hand 8.04M
Cost of revenue 2.51M 3.31M 2.9M 3.16M
Annual (USD) Sep 19 Sep 18 Sep 17 Sep 16
Revenue 31.8M 15.86M 13.66M 22.13M
Net income -12.02M -23.94M -6.61M 344.73K
Diluted EPS -0.19 -0.44 -0.25 0.01
Net profit margin -37.79% -151% -48.42% 1.56%
Operating income -6.44M -20.87M -8.49M 3.02M
Net change in cash 481.91K 892.52K -1.72M
Cash on hand 3.76M 3.28M 2.39M
Cost of revenue 10.15M 7.09M 6.64M 8.78M

Financial data from Veru earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
21 Feb 20 Fisch Harry Common Stock Buy Aquire P 4.47 1,000 4.47K 859,025
20 Feb 20 Fisch Harry Common Stock Buy Aquire P 4.51 1,000 4.51K 858,025
19 Feb 20 Jesus Socorro Common Stock Buy Aquire P 4.27 5,000 21.35K 32,500
19 Dec 19 Jesus Socorro Common Stock Buy Aquire P 2.7999 5,000 14K 27,500
5 Dec 19 Steiner Mitchell Shuster Common Stock Sell Dispose S 2.221 16,590 36.85K 7,434,767
4 Dec 19 Steiner Mitchell Shuster Common Stock Sell Dispose S 2.199 8,410 18.49K 7,451,357
13F holders
Current Prev Q Change
Total holders 0 0 NaN%
Opened positions 0 0 NaN%
Closed positions 0 0 NaN%
Increased positions 0 0 NaN%
Reduced positions 0 0 NaN%
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

CanadaAllerganOpexa TherapeuticsHCIPathAllergan
  • COVID-19 and its impact on the economic environment and capital markets could adversely affect our access to capital when needed.
  • We may not be entitled to forgiveness of our recently received PPP Loan, and our application for the PPP Loan could in the future be determined to have been impermissible or could result in damage to our reputation.
Management Discussion
  • The Company generated net revenues of $9.9 million and net loss of $0.8 million, or $(0.01) per basic and diluted common share, for the three months ended March 31, 2020, compared to net revenues of $7.0 million and net loss of $4.0 million, or $(0.07) per basic and diluted common share, for the three months ended March 31, 2019. Net revenues increased 43% year over year.
  • FC2 net revenues represented 96% of total net revenues for the three months ended March 31, 2020. FC2 net revenues increased 39% year over year. There was a 30% decrease in total FC2 unit sales and an increase in FC2 average sales price per unit of 98%. The principal factor for the increase in the FC2 average sales price per unit compared to prior year was the increase in net revenues in the U.S. prescription channel. The Company experienced an increase of 168% in FC2 net revenues in the U.S. prescription channel and a decrease of 40% in FC2 net revenues in the global public sector.
  • Cost of sales increased to $2.5 million in the three months ended March 31, 2020 from $2.4 million in the three months ended March 31, 2019 primarily due to an increase in labor, transportation, and equipment maintenance costs.
Content analysis ?
H.S. junior Avg
New words: Acute, advantage, alive, altogether, antitumor, antiviral, attempt, BARDA, baseline, binding, Biomedical, bone, broad, burden, candidate, certainty, chemotherapy, civil, claim, clarity, clear, colchicine, combat, combating, commerce, commitment, committing, contact, controversy, criminal, CT, CTAP, cycle, cytokine, DARPA, death, decided, declared, decline, demonstrated, Department, depolymerization, diarrhea, discontinuation, discontinue, dissipate, distancing, diversion, diverted, documentation, documented, economy, efficacy, effort, eligibility, eligible, emerged, emergency, encounter, endpoint, entirety, escalated, exemption, expedite, faith, fallen, False, fatigue, forced, forgivable, forgiven, freely, furlough, good, headcount, high, hospital, hospitalization, hospitalized, imaging, impede, impermissible, important, imposed, imposing, indirectly, induced, ineligible, infection, inhibit, interpretation, interrupted, interruption, intracellular, job, lack, lender, long, longevity, mandatory, maturity, mechanical, media, median, microtubule, mild, mitigate, monitor, monitoring, monthly, mortality, mortgage, MTD, national, nausea, neurotoxicity, neutropenia, obsolete, ordinal, oversee, pandemic, Paycheck, payroll, penalty, permission, pivotal, postpone, PPP, prechemotherapy, preliminary, prioritize, prioritized, prioritizing, proceeding, progression, proportion, PSA, pulmonary, pursuit, randomized, rapid, rapidly, RECIST, recommended, recruit, recruiting, recruitment, reevaluate, refuse, rely, reopen, reopening, repay, run, safety, salary, SBA, scale, schedule, scientific, Secondary, serum, sheath, sheltering, site, situation, social, soft, Solid, spiked, spread, stable, stopping, storm, strain, strong, suffering, supplier, surgical, surveillance, suspended, syndrome, temporarily, therapeutic, threat, tissue, tolerated, trafficking, tumor, unexpected, unintended, unprecedented, unwilling, urgent, ventilation, viral, vomiting, worker, workforce, worsen
Removed: exceed, filed, movement, population, realized, region, Ringgit, vulnerable